NCT04138719 - Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer | Biotech Hunter

Enrollment

520

Participants

Timeline

Start Date

November 20, 2019

Primary Completion Date

October 20, 2026

Study Completion Date

June 20, 2028

Conditions

Breast CancerTriple-negative Breast CancerNab-paclitaxel

Interventions

DRUG

Nab-paclitaxel + Carboplatin

nab-paclitaxel given IV at 125 mg/m\^2 on days 1, 8 and carboplatin given IV at AUC 5 on days 1 every 21 days x 6 cycles;

DRUG

Nab-paclitaxel + Epirubicin

nab-paclitaxel given IV at 125 mg/m\^2 on days 1, 8 and epirubicin given IV at 75 mg/m\^2 on days 1 every 21 days x 6 cycles；

Trial Locations (1)

RECRUITING

The Fourth Hospital of Hebei Medical University, Shijiazhuang